Applied Therapeutics Stock Fundamentals
| APLT Stock | USD 9.63 0.36 3.88% |
Applied Therapeutics fundamentals help investors to digest information that contributes to Applied Therapeutics' financial success or failures. It also enables traders to predict the movement of Applied Stock. The fundamental analysis module provides a way to measure Applied Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Applied Therapeutics stock.
At this time, Applied Therapeutics' Net Interest Income is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 21.9 M in 2024, despite the fact that Gross Profit is likely to grow to (41.7 M). Applied | Select Account or Indicator |
Applied Therapeutics Company Shares Outstanding Analysis
Applied Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Applied Therapeutics Shares Outstanding | 116.36 M |
Most of Applied Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Applied Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Applied Shares Outstanding Historical Pattern
Today, most investors in Applied Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Applied Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Applied Therapeutics shares outstanding as a starting point in their analysis.
Applied Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Applied Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Applied Therapeutics has 116.36 M of shares currently outstending. This is 35.55% lower than that of the Biotechnology sector and 8.89% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 79.65% higher than that of the company.
Applied Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Applied Therapeutics's current stock value. Our valuation model uses many indicators to compare Applied Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Applied Therapeutics competition to find correlations between indicators driving Applied Therapeutics's intrinsic value. More Info.Applied Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Applied Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Applied Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Applied Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Applied Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Applied Therapeutics could also be used in its relative valuation, which is a method of valuing Applied Therapeutics by comparing valuation metrics of similar companies.Applied Therapeutics is currently under evaluation in shares outstanding category among its peers.
Applied Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Applied Therapeutics from analyzing Applied Therapeutics' financial statements. These drivers represent accounts that assess Applied Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Applied Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 350.0M | 483.5M | 229.1M | 28.7M | 282.2M | 176.7M | |
| Enterprise Value | 333.2M | 427.8M | 176.5M | 13.0M | 233.1M | 152.4M |
Applied Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Applied Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Applied Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Applied Fundamentals
| Return On Equity | -4.73 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (243.80) % | ||||
| Current Valuation | 981.73 M | ||||
| Shares Outstanding | 116.36 M | ||||
| Shares Owned By Insiders | 5.23 % | ||||
| Shares Owned By Institutions | 94.77 % | ||||
| Number Of Shares Shorted | 12.14 M | ||||
| Price To Earning | (7.46) X | ||||
| Price To Book | 183.07 X | ||||
| Price To Sales | 54.68 X | ||||
| Revenue | 9.99 M | ||||
| EBITDA | (64.53 M) | ||||
| Net Income | (119.76 M) | ||||
| Cash And Equivalents | 67.72 M | ||||
| Cash Per Share | 1.41 X | ||||
| Total Debt | 777 K | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 1.49 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (55.17 M) | ||||
| Short Ratio | 7.18 X | ||||
| Earnings Per Share | (1.42) X | ||||
| Target Price | 14.67 | ||||
| Number Of Employees | 37 | ||||
| Beta | 2.02 | ||||
| Market Capitalization | 1.12 B | ||||
| Total Asset | 54.83 M | ||||
| Retained Earnings | (468.59 M) | ||||
| Working Capital | (16.8 M) | ||||
| Current Asset | 37.74 M | ||||
| Current Liabilities | 11.19 M | ||||
| Net Asset | 54.83 M |
About Applied Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Applied Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Applied Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Applied Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 600.3 K | 570.3 K | |
| Total Revenue | 10 M | 10.5 M | |
| Cost Of Revenue | 53.9 M | 56.6 M | |
| Stock Based Compensation To Revenue | 0.66 | 0.59 | |
| Sales General And Administrative To Revenue | 1.86 | 1.65 | |
| Research And Ddevelopement To Revenue | 4.85 | 4.31 | |
| Revenue Per Share | 0.11 | 0.10 | |
| Ebit Per Revenue | (5.81) | (6.10) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.